Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Justin Chura, MD, and Anya Khomenko, survivor of ovarian cancer, reinforce the value in patient education and reflect on the importance of seeking a second opinion from an expert in ovarian cancer prior to beginning therapy.
Justin Chura, MD, discusses the role of the gynecologic oncologist in establishing an initial treatment plan for newly diagnosed patients with ovarian cancer and helping patients, such as Anya Khomenko, prepare for every step along the way.
Justin Chura, MD, and Anya Khomenko, survivor of cancer, remark on later-stage diagnoses in ovarian cancer and the wide range of nonspecific symptoms that can occur, advising viewers to pay attention to warning signs.
Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond.